Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.
Keefe Bruyette trimmed its price target on Pagaya Technologies (PGY) to $35, while maintaining an Outperform rating. The adjustment comes despite the AI-driven lending platform reporting robust Q3 growth and a record partner pipeline.
Truist Securities has increased its price target for Nuvation Bio, highlighting the promising early commercial traction of its oncology drug Ibtrozi, which is outpacing competitors in the ROS1 inhibitor space.
UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
Wall Street firms Keefe Bruyette and BTIG have raised price targets on Core Scientific, citing the company's strategic shift from Bitcoin mining to high-performance computing infrastructure for AI as a key driver for future growth.
Barclays raises Astera Labs' price target to $165, naming it a top pick for AI integration plays in its 2026 semiconductor outlook, while contrasting analyst views highlight the evolving debate on AI's infrastructure demands.
The UK-based payments technology firm Bango (LON:BGO) is showing early signs of a financial transformation, breaking into profitability and increasing its capital deployment. While its return on capital remains below the software industry average, the underlying trend suggests a company in the midst of a strategic pivot.
PennyMac Mortgage Investment Trust (PMT) reported a robust fourth quarter, highlighted by a 13% return on equity and strategic advancements in its securitization business. Executives outlined a confident outlook for 2026, emphasizing disciplined risk management and growth in targeted lending segments.
Facing a tough freight environment, Schneider National's leadership outlines a strategy centered on cost discipline, tech investment, and strategic positioning in intermodal and dedicated services to steer toward future profitability.
Olin Corporation is closing its Guarujá epoxy facility as part of a broader cost-cutting initiative, responding to soft chlorine demand and operational headwinds. The company pins a turnaround for its Epoxy segment on 2026, while its Winchester ammunition unit raises prices to counter inflation.
Meritage Homes shares have lagged peers over the past year, but a detailed valuation analysis suggests a significant gap between its current price and estimated intrinsic value. We examine the DCF and P/E metrics fueling the debate.
Thyssenkrupp AG's stock has skyrocketed over the past year, leaving investors to grapple with a critical question: does the German industrial giant still offer value, or is it now overhyped? We delve into the valuation metrics, market context, and expert perspectives to separate signal from noise.
Amidst a market often captivated by speculative narratives, Centurion Corporation stands out with a track record of robust profit growth and significant insider confidence. We examine the key metrics and signals making this industrial accommodation provider a name to watch.
Axos Financial Inc. (AX) reported robust second-quarter earnings for fiscal 2026, highlighted by a 23.3% surge in earnings per share and significant loan portfolio expansion, even as it manages industry-wide margin pressures and rising operational costs.
First Internet Bancorp (INBK) reported a robust 21% surge in quarterly revenue, successfully managing an uptick in criticized loans while laying the groundwork for growth in its fintech and SBA lending segments for the coming year.
Despite a 4.3% year-over-year revenue decline in Q3 FY2026, DXC Technology outlines a strategic pivot, leveraging its legacy systems and AI to build scalable IP and shift toward value-based pricing models.
Shares of Singapore's Wee Hur Holdings Ltd. (SGX:E3B) have climbed 24% in the past quarter, outpacing broader market trends. While its Return on Equity appears modest, aggressive reinvestment of profits and a strategic shift in its business model may be fueling investor optimism and the recent price momentum.
Despite a powerful multi-year rally, new analysis suggests The Hartford's stock may still be trading at a significant discount. We examine the valuation metrics and market sentiment surrounding the insurance giant.
Amidst a complex backdrop of economic crosscurrents and geopolitical tensions, a select group of small-cap companies across Asia are demonstrating remarkable resilience and growth potential. We analyze three standout names from Singapore and China that are navigating the volatility with strong fundamentals.
